Paladin and Watson Enter Into Marketing and Supply Agreement for Trelstar'R' in Canada.MONTREAL -- Paladin Labs Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :PLB (Picture Level Benchmark) A benchmark for measuring graphics performance on workstations. The Benchmark Interface Format (BIF) defines the format, the Benchmark Timing Methodology (BTM) performs the test, and the Benchmark Reporting Format (BRF) generates results in ), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a Canadian marketing and supply agreement with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE NYSE See: New York Stock Exchange :WPI WPI - Worcester Polytechnic Institute ) to market Trelstar(R) 3.75 mg and Trelstar(R) LA 11.25 mg (triptorelin pamoate for injectable suspension).Trelstar(R) 3.75 mg, 1 month slow release, is an injectable, luteinizing hormone-releasing hormone luteinizing hormone-releasing hormone n. Abbr. LHRH, LRH See gonadotropin-releasing hormone. (LHRH LHRH abbr. luteinizing hormone-releasing hormone LHRH Luteinizing hormone-releasing hormone, GnRH, gonadotropin-releasing hormone, LRH, LRF Endocrinology A decapeptide synthesized by hypothalamic neurons which ) agonist indicated for the palliative treatment of advanced prostate cancer and for the treatment of endometriosis.Trelstar(R) LA 11.25 mg, 3 month slow release, is an injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer.Trelstar(R) 3.75 mg and Trelstar(R) LA 11.25 mg are approved for sale in Canada. "Trelstar(R) represents our third product deal with Watson and follows on our successful in-license and launch of Oxytrol(R) late last year.We are proud that Watson continues to demonstrate confidence in our commercialization capabilities and has selected us to be their partner of choice for Canada," said Jonathan Ross Goodman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Paladin Labs. Trelstar(R) will further strengthen Paladin's urology presence in Canada by complementing the existing promotional activities with Oxytrol(R).In addition Trelstar(R) 3.75 mg will also complement the women's health franchise since it has been approved for the treatment of endometriosis.Paladin expects to launch Trelstar(R) and Trelstar(R) LA in the fourth quarter of 2005.According to IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. Canada, the Canadian market for LHRH agonists for prostate cancer and endometriosis exceeded $125 million in 2004. About TRELSTAR(R) Trelstar(R) 3.75mg and Trelstar(R) LA 11.25mg (triptorelin pamoate for injectable suspension), formulated using Debiopharm S.A.'s Debio(R) PLGA PLGA Poly-Lactic-Co-Glycolic Acid PLGA Plastic Land Grid Array PLGA Physically Limited Golfers Association proprietary technology, are one and three-month sustained-release formulations of triptorelin, an analog of luteinizing hormone-releasing hormone (LHRH or GnRH) with greater potency than naturally occurring LHRH.The products are approved for the treatment of advanced prostate cancer and Trelstar(R) 3.75 is also approved for the treatment of endometriosis in Canada.In clinical trials, the two most common adverse events were hot flushes and skeletal pain.Trelstar(R) LA 11.25 mg is contraindicated for use in women who are or may become pregnant and should not be administered to patients who are hypersensitive hy·per·sen·si·tive adj. Responding excessively to the stimulus of a foreign agent, such as an allergen; abnormally sensitive. hy to triptorelin and other components of the product, other LHRH agonists or LHRH. For more information about Trelstar(R) and Trelstar(R) LA, detailed product profiles are available at www.trelstar.com. For more information about Trelstar(R) and Trelstar(R) LA, a detailed product profile is now available in the products section of Paladin's Web site http://www.paladinlabs.com/our_products/selected_products_in_developme nt.html#trelstar About Paladin Labs Inc. Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market.With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies.Paladin's shares trade on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol PLB.For more information about Paladin, please visit the Paladin Web Site at www.paladinlabs.com. This news release may contain forward-looking statements or predictions.These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements.Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval and other factors that are discussed in the Management Discussion and Analysis published in the Company's annual report. Trelstar(R) is a registered trademark of Watson Laboratories, Inc. PALADIN LABS INC. (TSX:PLB) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion